Lumida
/NGNE
⌘K
Neurogene Inc

Neurogene Inc

NGNE
$35.48USD-1.77%-0.64 today

MARKET CAP

710.0M

P/E (TTM)

FWD P/E

DAY RANGE

$35 – $38

52W RANGE

$16
$44

AI Summary

Stalk
Buy NowMedium

The stock maintains a bullish medium- and long-term structure, anchored by rising major moving averages and a sequence of higher lows. A recent pullback into the 9/21 EMA support zone was absorbed, signaling acceptance and a favorable entry bias. RSI holds in neutral territory, avoiding overbought extremes. Execution is recommended now, buying into minor pullbacks toward the EMA support area.

  • Phase 1/2 NGN-401 trial saw 100% participants improving, averaging 4.7 milestones
  • Analysts’ average $83.67 target implies ~135% potential upside
  • Q2 net loss of $34.5M (-$1.53/share) underscores cash burn
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2024TREND
Sales, Adj.$925,000
YoY %
P / Sales434.1x
EV / Sales313.9x
Gross Profit, Adj.$925,000
YoY %
Margin %100.0%
EV / Gross Profit313.9x
EBITDA, Adj.$-79.4M
YoY %-51.9%
Margin %-8584.9%
EV / EBITDA-3.7x
EBIT$-82.6M
YoY %-48.6%
Margin %-8930.3%
EV / EBIT-3.5x
Net Income$-75.1M
YoY %-106.9%
Net Margin-8123.7%
EPS (GAAP)-$4.28
YoY %+89.2%